AARTIPHARM Share Price Performance
₹834.75
224.65 (36.82%)
Price ₹834.75
Share Price₹834.75
Aarti Pharmalabs Limited (NSE:AARTIPHARM) Not Lagging Market On Growth Or Pricing
Sep 25
Aarti Pharmalabs Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
AARTIPHARM Community Narratives
There are no narratives available yet.
Aarti Pharmalabs Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 29.40
- Gross Margin
- 50.11%
- Net Profit Margin
- 13.69%
- Debt/Equity Ratio
- 20.8%
Aarti Pharmalabs Limited Competitors
Snowflake Analysis
About AARTIPHARM
- Founded
- 2019
- Employees
- 2162
- CEO
- WebsiteView website
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Indian Market Performance
- 7 Days: 1.1%
- 3 Months: -0.1%
- 1 Year: -4.4%
- Year to Date: 1.3%
Over the last 7 days, the market has remained flat, although notably the Information Technology sector gained 3.3% in that time. Unfortunately though, the market is down 4.9% over the past year. Earnings are forecast to grow by 16% annually. Market details ›